RecruitingNCT06926192

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice

Sponsor

Peking Union Medical College

Enrollment

100 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Hidradenitis Suppurativa (HS)Secukinumab Hidradenitis Suppurativa (Acne Inversa)

Summary

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Eligibility

Max Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Surgery combined with secukinumab for people with hidradenitis suppurativa (acne inversa), hidradenitis suppurativa (hs), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.